Innovent Biologics (HKG:1801) recorded a total product revenue of over 2.4 billion yuan in the first quarter, up 40% from a year prior, a Thursday Hong Kong bourse filing said.
The drugmaker launched four new products in the quarter, comprising Dovbleron, Limertinib, and Jaypirca in the oncology niche, and SYCUME in the field of general biomedicine.
To date, the company has 15 approved products, three new drug applications under regulatory review, four assets in phase III or pivotal clinical trials, and 15 more molecules in early clinical stage.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。